According to Sarepta Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -14.9579. At the end of 2022 the company had a P/E ratio of -16.1.
Year | P/E ratio | Change |
---|---|---|
2022 | -16.1 | -7.71% |
2021 | -17.5 | -27.49% |
2020 | -24.1 | 80.9% |
2019 | -13.3 | -33.79% |
2018 | -20.1 | -72.14% |
2017 | -72.3 | 1338.35% |
2016 | -5.02 | -32.42% |
2015 | -7.43 | 74.15% |
2014 | -4.27 | -28.96% |
2013 | -6.01 | 19.25% |
2012 | -5.04 | -92.16% |
2011 | -64.3 | 809.7% |
2010 | -7.07 | 25.84% |
2009 | -5.62 | 189.28% |
2008 | -1.94 | -25.66% |
2007 | -2.61 | -55.66% |
2006 | -5.89 | -36.84% |
2005 | -9.32 | 173.78% |
2004 | -3.41 | -59% |
2003 | -8.31 | 89.38% |
2002 | -4.39 | -52.96% |
2001 | -9.32 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | 15.3 | -202.08% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | -2.94 | -80.36% | ๐บ๐ธ USA |
Novavax NVAX | -0.5828 | -96.10% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | -35.5 | 137.60% | ๐บ๐ธ USA |
Insmed INSM | -4.80 | -67.94% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | -3.50 | -76.57% | ๐บ๐ธ USA |
Avidity Biosciences RNA | -8.11 | -45.78% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.